---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-012595"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2022-07-11T23:59:59+00:00"
generated_at: "2026-06-24T17:32:35.697667+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences estimates $307M cash, cash equivalents and marketable securities as of June 30, 2022

## Summary
- Preliminary cash, cash equivalents and marketable securities balance of approximately $307 million as of June 30, 2022.
- Estimate is unaudited and subject to quarter-end closing adjustments.
- No other financial results for Q2 2022 provided; comprehensive statement not yet available.
- Company emphasizes this is a preliminary estimate and not a complete financial report.

## SEC filing metadata
- accession: 0000950170-22-012595
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2022-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017022012595/0000950170-22-012595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017022012595/kzr-20220711.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-012595
- JSON: https://secwatch.observer/filing/0000950170-22-012595.json
- Plain text: https://secwatch.observer/filing/0000950170-22-012595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.